Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Jongkwon | - |
dc.contributor.author | Ahn, Jung-Min | - |
dc.contributor.author | Hong, Sung-Jin | - |
dc.contributor.author | Kang, Yoon | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Her, Ae-Young | - |
dc.contributor.author | Kim, Yong Hoon | - |
dc.contributor.author | Ahn, Chul-Min | - |
dc.contributor.author | Kim, Jung-Sun | - |
dc.contributor.author | Kim, Byeong-Keuk | - |
dc.contributor.author | Ko, Young-Guk | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Jang, Yangsoo | - |
dc.contributor.author | Park, Seung-Jung | - |
dc.contributor.author | Park, Duk-Woo | - |
dc.contributor.author | Hong, Myeong-Ki | - |
dc.date.accessioned | 2021-08-30T21:30:36Z | - |
dc.date.available | 2021-08-30T21:30:36Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-06-01 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/55079 | - |
dc.description.abstract | Clinical benefits of bioresorbable vascular scaffold (BVS) implantation for long coronary lesions were not sufficiently evaluated. The efficacy and safety of BVS and metallic everolimus-eluting stent (EES) were compared for the treatment of long coronary narrowings. A total of 341 patients with diffuse long lesions (requiring device length >= 28 mm) were randomized to receive either BVS (n = 171) or EES (n = 170) implantation. The primary endpoint was major adverse cardiovascular events which included death from cardiac cause, myocardial infarction, device thrombosis, or ischemia-driven target-lesion revascularization at 12 months. The trial was terminated early because the manufacturer stopped supplying BVS. The mean lesion length was 32.2 +/- 13.1 mm in the BVS group and 35.3 +/- 13.0 mm in the EES group. The 12-month follow-up was completed in 332 patients (97.4%). At 12 months, the primary endpoint events occurred in 2 patients (1.2%) in the BVS group and in 4 patients (2.4%) in the EES group (hazard ratio = 0.49, 95% confidence interval = 0.09 to 2.67, p = 0.398). Definite or probable device thrombosis occurred in 1 patient (0.6%) in the BVS group and 1 patient (0.6%) in the EES group (hazard ratio = 1.00, 95% confidence interval = 0.06 to 15.94, p = 0.998). In conclusion, in patients with long native coronary artery disease, significant differences between BVS and EES were not observed regarding the primary composite endpoint of death from cardiac cause, myocardial infarction, device thrombosis, or target-lesion revascularization at 12 months. However, due to the early termination of this trial and a low number of events, the results cannot be considered clinically relevant (C) 2020 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | - |
dc.subject | DUAL ANTIPLATELET THERAPY | - |
dc.subject | IMPLANTATION | - |
dc.subject | TRIPLE | - |
dc.subject | CILOSTAZOL | - |
dc.subject | OUTCOMES | - |
dc.subject | IMPACT | - |
dc.subject | ARTERIES | - |
dc.subject | BLIND | - |
dc.title | Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, Soon Jun | - |
dc.identifier.doi | 10.1016/j.amjcard.2020.02.031 | - |
dc.identifier.scopusid | 2-s2.0-85082932023 | - |
dc.identifier.wosid | 000532793200004 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, v.125, no.11, pp.1624 - 1630 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 125 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1624 | - |
dc.citation.endPage | 1630 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | DUAL ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | IMPLANTATION | - |
dc.subject.keywordPlus | TRIPLE | - |
dc.subject.keywordPlus | CILOSTAZOL | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | ARTERIES | - |
dc.subject.keywordPlus | BLIND | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.